VRX, ZTS Amid Possible Targets in M&A ‘Feeding Frenzy’:Jefferies
2015-05-28 13:49:22.584 GMT
By Cristin Flanagan
(Bloomberg) -- Current M&A “feeding frenzy” may continue
unabated this year, Jefferies analyst David Steinberg writes in
note, although a poorly executed deal may shift investor
sentiment.
* Cheap debt, tax inversions, cash EPS accounting viewed as
drivers
* Lists possible targets:
* Among profitable cos: VRX, SHPG, PRGO, ZTS, MNK, JAZZ,
UTHR, PCRX, Indivior, INSY, MDCO, DEPO, SPPI
* Development stage cos: KYTH, RVNC, XNPT
* Generic drug cos: AKRX, AMPH, IPXL, MYL
* Special situation cos: ANAC, BDSI
* Special situation cos: ANAC, BDSI</li></ul>
* Notes large global buyers to watch: ACT, MYL, TEVA, Novartis
* In specialty pharma likely most active buyers: VRX,
SHPG, PRGO, MNK, ENDP, HZNP
* In specialty pharma likely most active buyers: VRX,
SHPG, PRGO, MNK, ENDP, HZNP</li></ul>
* PE acquirers haven’t been able to compete with strategic
buyers on ability to elicit oper, tax synergies
* NOTE: March 5, PCYC Deal Shows ‘Scarcity’; Highlights JUNO,
KITE, VRTX: RBC
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Cristin Flanagan in New York at +1-212-617-8919 or
cflanagan1@bloomberg.net
To contact the editors responsible for this story:
Arie Shapira at +1-212-617-1488 or
ashapira3@bloomberg.net
Cristin Flanagan
2015-05-28 13:49:22.584 GMT
By Cristin Flanagan
(Bloomberg) -- Current M&A “feeding frenzy” may continue
unabated this year, Jefferies analyst David Steinberg writes in
note, although a poorly executed deal may shift investor
sentiment.
* Cheap debt, tax inversions, cash EPS accounting viewed as
drivers
* Lists possible targets:
* Among profitable cos: VRX, SHPG, PRGO, ZTS, MNK, JAZZ,
UTHR, PCRX, Indivior, INSY, MDCO, DEPO, SPPI
* Development stage cos: KYTH, RVNC, XNPT
* Generic drug cos: AKRX, AMPH, IPXL, MYL
* Special situation cos: ANAC, BDSI
* Special situation cos: ANAC, BDSI</li></ul>
* Notes large global buyers to watch: ACT, MYL, TEVA, Novartis
* In specialty pharma likely most active buyers: VRX,
SHPG, PRGO, MNK, ENDP, HZNP
* In specialty pharma likely most active buyers: VRX,
SHPG, PRGO, MNK, ENDP, HZNP</li></ul>
* PE acquirers haven’t been able to compete with strategic
buyers on ability to elicit oper, tax synergies
* NOTE: March 5, PCYC Deal Shows ‘Scarcity’; Highlights JUNO,
KITE, VRTX: RBC
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Cristin Flanagan in New York at +1-212-617-8919 or
cflanagan1@bloomberg.net
To contact the editors responsible for this story:
Arie Shapira at +1-212-617-1488 or
ashapira3@bloomberg.net
Cristin Flanagan